Cullinan Therapeutics Statistics
Total Valuation
CGEM has a market cap or net worth of $466.81 million. The enterprise value is $164.82 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CGEM has 59.01 million shares outstanding. The number of shares has increased by 37.06% in one year.
| Current Share Class | 59.01M |
| Shares Outstanding | 59.01M |
| Shares Change (YoY) | +37.06% |
| Shares Change (QoQ) | +0.55% |
| Owned by Insiders (%) | 3.99% |
| Owned by Institutions (%) | 82.25% |
| Float | 39.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.80 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.62, with a Debt / Equity ratio of 0.00.
| Current Ratio | 11.62 |
| Quick Ratio | 11.11 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -36.57% and return on invested capital (ROIC) is -26.58%.
| Return on Equity (ROE) | -36.57% |
| Return on Assets (ROA) | -25.38% |
| Return on Invested Capital (ROIC) | -26.58% |
| Return on Capital Employed (ROCE) | -37.83% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.61M |
| Employee Count | 111 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CGEM has paid $117,000 in taxes.
| Income Tax | 117,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.23% in the last 52 weeks. The beta is -0.07, so CGEM's price volatility has been lower than the market average.
| Beta (5Y) | -0.07 |
| 52-Week Price Change | -70.23% |
| 50-Day Moving Average | 8.13 |
| 200-Day Moving Average | 12.81 |
| Relative Strength Index (RSI) | 47.98 |
| Average Volume (20 Days) | 460,264 |
Short Selling Information
The latest short interest is 7.48 million, so 12.67% of the outstanding shares have been sold short.
| Short Interest | 7.48M |
| Short Previous Month | 7.99M |
| Short % of Shares Out | 12.67% |
| Short % of Float | 18.94% |
| Short Ratio (days to cover) | 14.69 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -208.93M |
| Pretax Income | -156.28M |
| Net Income | -178.74M |
| EBITDA | -208.62M |
| EBIT | -208.93M |
| Earnings Per Share (EPS) | -$3.10 |
Full Income StatementBalance Sheet
The company has $303.83 million in cash and $1.84 million in debt, giving a net cash position of $301.99 million or $5.12 per share.
| Cash & Cash Equivalents | 303.83M |
| Total Debt | 1.84M |
| Net Cash | 301.99M |
| Net Cash Per Share | $5.12 |
| Equity (Book Value) | 551.84M |
| Book Value Per Share | 9.40 |
| Working Capital | 290.42M |
Full Balance SheetCash Flow
| Operating Cash Flow | -150.21M |
| Capital Expenditures | n/a |
| Free Cash Flow | -150.21M |
| FCF Per Share | -$2.55 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |